Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
IDEXX LaboratoriesAbbVie
Last price
$560.38$285.64
Currency
USD
USD
$44B$505B
39.4080.70
$14.22$3.54
1.550.28
0$6.83
02.42%
Sector
HealthHealth
Employees
11,00057,000
Ticker
$IDXX$ABBV
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $IDXX or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.